As well as discussing exenatide, the recent SoPD post also discusses research on another GLP-1 receptor agonist called NLY01. A recent AlzForum article also provides a good overview/discussion of this NLY01 research (IMHO).
"NLY01 is on a fast track to human testing … with the goal of a Phase 2 in Parkinson’s disease in 2019."
Does Taming Killer Astrocytes Spare Neurons in Parkinson’s Disease? | ALZFORUM